Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

29.01 -0.13 (-0.45%)
Streaming Delayed Price Updated: 1:12 PM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 182,787
Open 29.21
Bid (Size) 28.98 (300)
Ask (Size) 29.04 (200)
Prev. Close 29.14
Today's Range 28.77 - 29.36
52wk Range 4.300 - 40.37
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Capricor (CAPR) Q1 2026 Earnings Transcript ↗
Capricor (CAPR) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Capricor Therapeutics Q1 Earnings Call Highlights ↗
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself... 
Via MarketBeat
Topics Earnings

Performance

YTD
+2.5%
+2.5%
1 Month
-17.4%
-17.4%
3 Month
+2.3%
+2.3%
6 Month
+459.0%
+459.0%
1 Year
+176.8%
+176.8%

More News

Read More
Capricor Therapeutics Inc (NASDAQ:CAPR) Q1 Results Show EPS Miss as Market Awaits August PDUFA Date ↗
Via Chartmill
News headline image
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story ↗
Via The Motley Fool
Topics Regulatory Compliance
Capricor Therapeutics Inc (NASDAQ:CAPR) Reports Q4 2025 Loss, Focus Remains on FDA Review for Deramiocel ↗
Via Chartmill
News headline image
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval ↗
Via Stocktwits
Topics Earnings
News headline image
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval ↗
Via Stocktwits
Topics Earnings
News headline image
Capricor (CAPR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy ↗
Via Stocktwits
News headline image
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures ↗
Via Stocktwits
News headline image
CAPR Stock Surged 17% Today — What’s Fueling The Rally? ↗
Via Stocktwits
News headline image
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains ↗
Via Stocktwits
News headline image
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On ↗
Via Stocktwits
News headline image
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
Via Stocktwits
News headline image
Here's Why This Biotechnology Skyrocketed by 439% in December ↗
Via The Motley Fool
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗
Via Stocktwits
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗
Via Stocktwits
News headline image
Why Did Capricor Therapeutics Stock Skyrocket Today? ↗
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Point To Steady Open: Why CAPR, MRVL, AEO, GTLB, CRWD Are On Traders' Radar ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 29.01
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 05/28/26 01:12 PM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 1.33B
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.